The Effects of the Addition of Micronised Fenofibrate on Uric Acid Metabolism in Patients Receiving Indapamide

Autor: Evagelos N. Liberopoulos, Spyros N Nikas, Apostolos Achimastos, Vasilios Tsimihodimos, George Miltiadous, Eleni Bairaktari, Moses Elisaf
Rok vydání: 2002
Předmět:
Male
medicine.medical_treatment
Uric Acid/blood/*metabolism/urine
Urine
Hypertension/*drug therapy
Fibrinogen/analysis
chemistry.chemical_compound
Fenofibrate
Medicine
Hyperuricemia
Hypolipidemic Agents
Indapamide
General Medicine
Middle Aged
Triglycerides/blood
Cholesterol
Cholesterol
LDL/blood
Hypertension
Indapamide/*administration & dosage/adverse effects
Drug Therapy
Combination
Female
Antihypertensive Agents/*administration & dosage/adverse effects
medicine.drug
Adult
medicine.medical_specialty
Hyperlipidemias/*drug therapy
Hyperlipidemias
Cholesterol/blood
Hypolipidemic Agents/*administration & dosage/pharmacology
Fenofibrate/*administration & dosage/pharmacology
Pharmacokinetics
Internal medicine
Humans
Antihypertensive Agents
Triglycerides
Aged
Apolipoproteins B
business.industry
Fibrinogen
Cholesterol
LDL
medicine.disease
Uric Acid
Apolipoproteins B/blood
Blood pressure
Endocrinology
chemistry
Uric acid
Diuretic
business
Zdroj: Current Medical Research and Opinion. 18:59-63
ISSN: 1473-4877
0300-7995
DOI: 10.1185/030079902125000273
Popis: OBJECTIVE: Hyperuricaemia is associated with indapamide administration. In contrast, micronised fenofibrate can significantly decrease serum uric acid levels. However, there are no data on the effect of combination therapy of indapamide with micronised fenofibrate on uric acid metabolism. METHODS: We studied 20 non-diabetic hypertensive patients with mixed dyslipidaemia in whom serum metabolic parameters, including uric acid levels in serum and urine, were measured before and after eight weeks of indapamide administration (2.5 mg once daily). This study was continued for a further eight weeks, when the indapamide was combined with micronised fenofibrate (200 mg once daily). RESULTS: Indapamide significantly decreased mean systolic and diastolic blood pressure (BP) from 153 +/- 9/97 +/- 8 mmHg to 138 +/- 8/93 +/- 4 mmHg (p< 0.05 for both comparisons). A significant increase in serum uric acid levels occurred after indapamide administration (from a mean value of 5.6 +/- 1.3 mg/dl (0.33 +/- 0.07 mmol/l) to 6.4 +/- 1.1 mg/dl (0.38 +/- 0.06 mmol/l), p < 0.01]. This effect was associated with a decrease in the fractional excretion of uric acid (from a mean value of 9.5 +/- 5% to 7 +/- 5.5%, p < 0.05). The addition of micronised fenofibrate significantly decreased plasma fibrinogen levels as well as total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B (ApoB) and triglycerides, and increased high-density lipoprotein cholesterol and ApoA, levels. Fenofibrate administration was followed by a significant decrease in serum uric acid levels to 4.7 +/- 1.2 mg/dl (0.28 +/- 0.07 mmol/l), p < 0.01, owing to a substantial increase in fractional urate excretion to 11 +/- 3%, p < 0.01. CONCLUSION: The addition of micronised fenofibrate can correct the hyperuricaemic effect of indapamide administration. Current Medical Research and Opinion
Databáze: OpenAIRE
Externí odkaz: